Phase II Study of Amrubicin in Patients with Refractory or Resistant Relapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901)

Autor: Masaharu Nishimura, G. Galffy, Q. Cheng, N. Stjepanovic, B. B. Oven Ustaalioglu, M.A. Damiano, G. Sajjady, J. Cai, B. Wallin, J. Dimitroulis, M. Reck, Judit Kocsis, B. Dome, S. Mellor, Y. Okuma, G. Le Teuff, N. Muzzafar, S. Yang, T. Tamura, S.A. Kazmi, G. Fust, H. Isobe, L. Graf, R. Eckert, D. Easty, S. Ahn, M. Chacon, D.A. Fennell, H. Daga, D. Pérez-Callejo, Raffaele Califano, Y. Ohe, Angela C. Casbard, Pablo Martinez, Y. Hosomi, H. Murakami, M. Salcedo, Y-C. Kim, Mustafa Canhoroz, Y. Fujita, A. Verlicchi, I. Oh, M.A. Burgio, S. Imtiaz, C. Kurkjian, M.A. Montero, A. Rosales, D. Pérez Callejo, C. Park, P. Ibeas, Susana Cedres, S. Heavey, Thierry Jahan, X. Wang, K. Kim, G. Stathopoulos, W. Sterlacci, M. Palka, N.B. Leighl, Satoshi Oizumi, Benjamin Besse, E. Almagro Casado, G. Gavelli, M. Yomoda, K. Takamura, C. Maximiano, J.W. Heyburn, Selcuk Seber, C. Lou, Wolfgang Hilbe, L. Tamasi, W. Mao, L. Ampollini, A. Santo, Jason F. Lester, D. Simos, H. Yang, J-C. Soria, H. Jamnig, S. Kuom, H. Ban, S. Sanna, Gareth Griffiths, Y. Ichinose, K. Na, D. Tsavdaridis, Taner Korkmaz, Z. Segota, R. Buosi, Lisette Sheena Nixon, G. Pall, K.A. Gately, M. Leschke, C. Martin, T. Schmid, P. Godwin, Hirotoshi Dosaka-Akita, M.E. Guiterrez, L. Lei, J. Edwards, C. Ho, Z. Prohaszka, David Planchard, H. Lu, Athanassios Argiris, J. Qin, M. Nevinny, Yvonne Summers, Y. Takagi, M. Endo, K.J. O'Byrne, T. Okamura, Z. Orosz, B. Cantos, A. Martinez, A. Falco, M. Mezzetti, E. Flechter, H. Watanabe, Umut Kefeli, G. Zangerl, M.S. Liew, R. Hassan, Serdar Turhal, A.C. Mita, I.A. Muazzam, Z. Bartfai, D. Nonaka, O.S. Breathnach, M. Monti, Harvey I. Pass, C. Poleri, O. Balvan, S. White, L. Mutti, J. Margery, W. Kim, Hedy L. Kindler, Hajime Asahina, M. Rosenberg, Mahmut Gumus, A. Pircher, A. López-González, N. Siddiqui, D. Torrejon Castro, V. Vilchez, R. Chacon, Dean A. Fennell, K. Umezawa, A. Szilagyi, T. Kojima, R. Mastico, Enriqueta Felip, Y. Zhang, P. Wheatley-Price, R. Guild, Rastilav Bahleda, D. Traphalis, M. Sergi, O. Ben Itzhak, T. Shibata, A.K. Patané, K. Das, S. Kumar, O. Vaisman, J. Stathopoulos, N. Yasar, W.M. Grogan, A. Soltermann, Steven G. Gray, H. Kang, J. Clince, M. Faehling, C.L. Hann, M. Barr, Lyudmila Bazhenova, B.G. Doger de Speville, A. Ruiz-Valdepeñas, Anne-Marie Baird, C. Kosmas, Y. Nakahara, T. Harada, J.D. Maltzman, M. Provencio Pulla, J. Parno, N. Yamamoto, M. Wollner, Antoine Hollebecque, David R. Spigel, Willi Oberaigner, Y. Kawai, M. Shibuya, E. Sari, E. Almagro-Casado, M. Mendez Garcia, N.J. Coleman, J. Raphael, Johanna C. Bendell, M. Fiegl, I. Opitz, G. Diaz, E. Jennions, Christophe Massard, G. Genestreti, M. Iguchi, P. Fatato

Publikováno v: Annals of Oncology. 23:ix492

Background Standard therapy for refractory or resistant relapsed small-cell lung cancer (SCLC) has not yet been established. We conducted an open-label, multicenter, non-randomized phase II study to confirm the efficacy and safety of amrubicin, a top

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3285e282bfecba0a422afa8f2b2c30d7
https://doi.org/10.1093/annonc/mds415